Poster ID - **P0817**

DUCRAY
SCIENCE DERMATOLOGIQUE

INTEREST OF AN ANTI HAIR LOSS SERUM CONTAINING *SILYBUM MARIANUM*, *LESPEDEZA CAPITATA* AND MANGANESE PYRROLIDONE CARBOXYLIC ACID IN CHRONIC HAIR LOSS MANAGEMENT: AN INTERNATIONAL REAL-WORLD STUDY

Valèrie Mengeaud[1], Alexia Brocario[1], Eva Mantel[1], Virginie Ribet[1], Bianca Maria Piraccini[2]
1. Medical Direction, DUCRAY, Les Cauquillous, Lavaur, France
2. Piraccini Medical Center, Bologna, Italy

INTRODUCTION & OBJECTIVES

Non-cicatricial hair disorders entail diminished visible hair and can significantly impact psychosocial well-being and overall quality of life. The most common form is androgenic alopecia (AGA). Chronic telogen effluvium (CTE) is more frequent in adult females. Senescent alopecia (SA) affects people aged 50 years or older and some cancer treatments can cause alopecia.

These results show the efficacy and tolerance of an anti-hair loss serum in AGA and CTE in monotherapy and in combination with treatments.

MATERIALS & METHODS

International, open label, real-world, prospective & multicentric study

Population

13 countries

1676 subjects

≥18 years old (mean age: 40)

66% **34%**

Phototypes I 1% | II 26% | III 42% | IV 24% | V 5% | VI 2%

Assessments at each visit:

✓ **Hair density & Global tolerance by dermatologists**


✓ **Hair density by subjects**

T0 — **T3 months** ± 3 weeks

*3 months of **daily-use** of the anti-hair loss serum (Anaphase Neoptide serum) on the scalp **in monotherapy** or **in association with treatments***

RESULTS

Chronic hair loss types



After **3 MONTHS**

Tolerance rated as 'good' to 'very good' by dermatologists for 95.1% of subjects


CONCLUSIONS

Regardless of the underlying cause of chronic hair loss, this serum offers patients a **reliable, effective,** and **well-tolerated** dermo cosmetic care solution.

Hair aspects assessed by dermatologists


Androgenetic alopecia

Hair density[2] in monotherapy




Chronic telogen effluvium

Hair loss (hair pull test) in monotherapy




Senescent alopecia

Hair density[2,3]



Post-cancer treatment alopecia


Hair density[2,3]



Hair density[2] assessed by subjects


Androgenetic alopecia

Monotherapy




Chronic telogen effluvium


Monotherapy



Senescent alopecia[3]



Post-cancer treatment alopecia[3]



After **3 MONTHS**

Androgenetic alopecia	Chronic telogen effluvium	Senescent alopecia	Post-cancer treatment alopecia
+33%** Hair density	**-64%**** Hair loss	**+30%**** Hair density	**+63%**** Hair density

After **3 MONTHS**

Androgenetic alopecia	Chronic telogen effluvium	Senescent alopecia	Post-cancer treatment alopecia
+37%** Hair density	**+49%**** Hair density	**+48%**** Hair density	**+75%**** Hair density

PRP: Platelet Rich Plasma
1. Stem-cell therapy, low level light therapy, micro needling and other emerging therapies.
2. Hair density was assessed using a Numerical Rating Scale from 0 (very slight) to 10 (very high). The reported number indicates the percentage change from baseline.
3. Results regardless of the prescription scheme for the anti-hair loss serum.

**p<0.001

Presented at the European Academy of Dermatology and Venereology Annual Congress, 30 September – 3 October 2026, Vienna, Austria